

Interim Report

July - September 2025



The increased interest we are witnessing in the market and from existing customers, together with the high pace of our product development, gives us a positive outlook for the future.

July-September 2025

- Net sales decreased by 13% and amounted to SEK 16.8 (19.4) million.
- Gross margin decreased to 26 (47)%.
- EBITDA amounted to SEK -4.4 (-0.2) million.
- Adjusted EBITDA* amounted to SEK -4.4 (-0.2) million.
- Net profit after tax amounted to SEK -5.9 (-4.5) million.
- Earnings per share before and after dilution amounted to SEK -0.13 (-0.10).

January-September 2025

- Net sales decreased by 8% and amounted to SEK 54.7 (59.2) million.
- The gross margin remained unchanged 40%.
- EBITDA amounted to SEK -10.4 (-9.2) million.
- Adjusted EBITDA* amounted to SEK -5.3 (-9.2) million.
- Net profit after tax amounted to SEK -14.9 (-15.0) million.
- Earnings per share before and after dilution amounted to SEK -0.34 (-0.34).

Significant events during and after the end of the period

- On 25 July, South Central Ambulance NHS Foundation Trust chose to extend its agreement for the provision of Ortivus MobiMed ePR for a further two years, with an order value of SEK 16.8 million.
- On 26 August, it was announced that the credit facility with Ponderus Invest AB had been increased by SEK 10 million.
- On 19 September, the Extraordinary General Meeting resolved to carry out a rights issue in accordance with the Board's proposal. The issue was registered on 3 November, resulting in the company receiving SEK 54.1 million before estimated issue costs of SEK 1.8 million. Subsequently, the debt to the main shareholder, Ponderus Invest AB, has been amortised by SEK 37 million.
- On 15 October, it was announced that the company's CFO, Johan Wewel, had chosen to leave the company for a position outside the Group.
- On 17 October, it was confirmed that Ponderus Invest AB's ownership had increased to 61% of the shares and 53% of the votes, thereby passing the mandatory bid threshold. Ponderus Invest has since announced that a mandatory takeover bid will be submitted no later than 3 December.

The Group's key figures*

Amount in tSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	16,849	19,412	54,650	59,151	80,413
Gross margin(%)	26%	47%	40%	40%	35%
Adjusted Gross margin	26%	47%	50%	40%	42%
EBITDA	-4,352	-186	-10,439	-9,238	-13,845
Adjusted EBITDA	-4,352	-186	-5,318	-9,238	-4,930
Operating profit	-5,441	-3,073	-13,177	-12,933	-19,532
Net profit after tax	-5,938	-4,530	-14,850	-15,015	-24,903
Equity ratio (%)	-37%	3%	-37%	3%	-11%
Earning per share, before and after dilution, SEK	-0.13	-0.10	-0.34	-0.34	-0.56
Equity per share, before and after dilution, SEK	-0.51	0.05	-0.51	0.05	-0.16

*See definitions of key figures, page 12.

CEO's Statement

Strengthened foundation for profitable growth

We have strengthened our financial position, laid the foundation for scalable growth, and are now seeing a clear increase in market demand.

The recently completed capital raise, which contributed approximately SEK 52 million net to the company, was a decisive step in reinforcing our balance sheet. A robust financial position is essential in our industry, where long and extensive contracts require stable and reliable partners. The capital will also be allocated to strengthening our development team. I would like to extend special thanks to our main shareholder, Ponderus AB, whose commitment has been instrumental in securing the financing and laying the groundwork for achieving sustainable profitability and positive cash flow in 2026.

We are now in the final phase of the transition we have been working on over the past 21 months. We are already seeing clear results in the form of increased organisational efficiency. The launch of MobiMed 5 and our new expanded offering, MobiMed for iOS, has further consolidated our position as a leading player in pre-hospital eHealth. The foundation has now been laid for a more stable and scalable growth phase.

Positive signals from the market

It is highly encouraging to see the strong response we are receiving from the market. Our existing customers have shown great interest in upgrading to MobiMed 5, our fifth-generation electronic patient record system, which reduces double documentation, improves usability, and includes advanced mass-casualty management features.

Equally exciting is the significant number of procurement processes planned within ambulance services across several markets over the next 24 months. Our unique and proven ability to integrate MobiMed with major hospital EHR systems such as Epic (in Singapore and Northern Ireland) and Cambio Cosmic (in Sweden) gives us a considerable competitive advantage in these processes.

A business model for sustainable and scalable growth

We continue to refine our business model to maximise the scalability characteristic of a modern software company. The model is built on recurring revenue from long-term software

contracts, combined with local project management and system configuration through partners. This structure enables us to manage multiple customer projects in parallel while maintaining quality and local presence – a key to profitable growth. The valuable, albeit costly, lessons learned from our project in Estonia have already been translated into concrete improvements in our project management model.

Outlook

The increased interest we are witnessing in the market and from existing customers, together with the high pace of our product development, gives us a positive outlook for the future. Our establishment in the Australian market marks an important step in our international expansion and opens the door to significant business opportunities going forward. The strategic decisions we have taken this year have created the right conditions to achieve profitable growth in the near future. There is strong and positive momentum within Ortivus.

Wishing you all a pleasant end to the year.



GUSTAF NORDENHÖK

Chief Executive Officer

Group development

July – September 2025

Financial performance

Net revenue for the quarter decreased by 13% and amounted to SEK 16.8 (19.4) million. For the period, net revenue decreased by 8% to SEK 54.7 (59.2) million. Of the period's net revenue, SEK 28.9 million relates to ongoing contracts. Compared with previous years, revenue was impacted by SEK -1.1 million due to a stronger Swedish krona. Revenue for the quarter was affected by lower project activity following the completion of the project in Estonia. Revenue decreased in the Nordic region but increased in the rest of Europe, primarily driven by hardware sales in the UK in connection with extended contracts. Gross margin for the quarter decreased to 26 (47)%. The gross margin was negatively impacted, among other factors, by the higher proportion of hardware in sales. Research and development costs decreased to SEK -1.2 (-2.2) million for the quarter and -4.5 (-8.9) for the period, with internal resources allocated to product development of the company's ePR for iOS and Windows. Operating expenses for the quarter decreased to SEK -9.9 (-12.2) million and to SEK -35.2 (-36.5) million for the period. The period's operating expenses were affected by the customer loss of SEK 5.1 million relating to the discontinued project in Estonia, as communicated in the Interim Report for January-June 2025. Operating profit for the quarter amounted to SEK -5.4 (-3.1) million and SEK -13.2 (-12.9) million for the period. Net financial items, primarily consisting of interest on loans and factoring, amounted to SEK -0.5 (-1.4) million for the quarter and -1.7 (-2.0) for the period, including a positive currency effect of SEK 1.2 million for the period. Profit after tax amounted to SEK -5.9 (-4.5) million for the quarter and SEK -14.8 (-15.0) million for the period. As the Group reports a negative result, the effective tax rate is zero. Tax loss carryforwards increased, and the Group does not recognise deferred tax on tax loss carryforwards.

Cash flow and liquidity

Cash flow from operating activities for the quarter amounted to SEK -4.8 (-15.6) million and SEK -14.4 (-20.9) million for the period. Cash flow from investing activities was SEK -1.9 (-1.3) million for the quarter and SEK -8.5 (-2.0) million for the period. Cash flow from financing activities generated SEK 5.1 (16.0) million in the quarter and SEK 15.6 (23.7) million for the period. The Group's total cash flow amounted to SEK -0.6 (-0.9) million for the quarter and SEK -6.3 (0.8) million for the half-year.

Financial position

Assets: Investments in intangible and tangible fixed assets amounted to SEK 38.0 (27.8) million at the end of the period. During the quarter, investments in intangible and tangible fixed assets totalled SEK 1.9 (-1.5) million and SEK 8.5 (-0.7) million for the period, depreciation for the quarter amounted to SEK 1.1 (2.9) million and SEK 3.6 (3.7) million for the period. These investments primarily related to ePR for iOS and MobiMed, aimed at broadening the offering with additional features. Financial assets amounted to SEK 2.3 (4.0) million. At the end of the period, inventories totalled SEK 5.1 (9.5) million. Trade receivables amounted to SEK 2.8 (6.5) million. Equity and liabilities: The Group's equity at the end of the period amounted to SEK -22.4 (2.4) million, with an equity ratio of -37 (3)%. Liabilities to Ponderus Invest AB amounted to SEK 53.9 million at the end of the period. The recently completed rights issue, registered on 3 November, has restored the Group's equity and equity ratio to secure levels.

The Group

The Group comprises the parent company Orivus AB (publ), corporate ID 556259-1205, and its wholly owned subsidiaries: Orivus UK Ltd, corporate ID 03558696; Orivus MobiMed AB, corporate ID 556593-0707; and Orivus MobiMed ApS, CVR 43419110 (under liquidation). A new subsidiary is being established in Australia. All subsidiaries are wholly owned.

Personnel

At the end of the period, the Group had 34 (32) employees, with 2 (2) in the Parent Company. Employees in Sweden numbered 29 (26). The proportion of women was 29%. In addition to employees, six consultants work within the organisation in various capacities.

Related party transactions

The existing credit facility from Ponderus Invest AB is valid until 31 December 2026. On 5 November, SEK 37 million was repaid to Ponderus Invest AB, leaving an outstanding loan balance of SEK 21.3 million. At the end of the period, Ponderus Invest AB holds 25.8% of the shares and is represented on the Board. Ponderus Invest AB has indicated that, as a result of the share issue, their ownership exceeds 30% and that information regarding any mandatory bid will be announced during the period 28 November – 3 December.

Shares, share capital and shareholders

Orivus A and B shares are listed on Nasdaq First North Growth Market. As of September 30, the number of shares was 44.3 million, comprising 1.7 million A shares and 42.6 million B shares. The number of shareholders was 3,923. The company's market capitalization at the end of the period was SEK 48.2 (75.7) million.

Forward-looking statements

All forward-looking statements in this report are based on the company's best assessment at the time of the report. Such statements involve risks and uncertainties, which may result in actual outcomes differing. Except as required by applicable law, forward-looking statements are valid only as of the date they are made, and Ortivus undertakes no obligation to update any of them in light of new information or future events. Ortivus does not provide forecasts.

Other information

The Parent Company Ortivus AB (publ) conducts group-wide operations. The parent company's net sales during the period amounted to SEK 8.0 (6.1) million. Operating profit amounted to SEK 2.1 (3.7) million. Cash and cash equivalents at the end of the quarter amounted to SEK 0.0 (0.8) million.

Certified Advisor

Certified Adviser on NASDAQ First North Growth Market is FNCA Sweden AB
Box 5807 Nybrogatan 34
102 48 Stockholm
Phone: +46 8 528 00 399

Financial calendar

Q4 and Full-Year Report: 19 February 2026
2025 Annual Report: 31 March 2026
Q1 2026 Report: 7 May 2026
Annual General Meeting: 7 May 2026

Financial information

Ortivus AB (publ) is listed on Nasdaq First North Growth Market. The information in this report is disclosed in accordance with the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication through the agency of the contact persons below on November 28 2025, at 08:30 a.m. CET. Financial reports and press releases are published in Swedish and English and are available at www.ortivus.com.

This report has not been reviewed by the company's auditor.

For further information:
Gustaf Nordenhök, CEO
Phone: 073-2624357
Email: gustaf.nordenhok@ortivus.com

Johan Wewel, CFO
Phone: 073-5073576
Email: johan.wewel@ortivus.com

Board's assurance

The Board of Directors and the CEO certify that this interim report provides a fair overview of the Parent Company's and the Group's operations, financial position, and results, and describes the significant risks and uncertainties facing the Parent Company and the companies in the Group.

Danderyd 28-11-2025



Anna-Carin Strandberg
Chairman of the Board



Peter Edvall
Board member



Anna Klevby Dalgaard
Board member



Ulf Järnberg
Board member



Gustaf Nordenhök
Chief Executive Officer

Financial Reports

The Group's report on results in summary

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	16,849	19,412	54,650	59,151	80,413
Cost of sales	-12,399	-10,305	-32,659	-35,635	-52,478
Gross profit	4,450	9,107	21,991	23,516	27,935
Gross margin	26%	47%	40%	40%	35%
Selling expenses	-4,542	-7,058	-15,095	-17,755	-24,813
Administrative expenses	-4,225	-3,236	-10,439	-9,449	-11,392
Research and development expenses	-1,246	-2,153	-4,534	-8,873	-10,805
Other operating income	579	246	674	246	349
Other operating expenses	-457	20	-5,774	-619	-805
Operating profit	-5,441	-3,073	-13,177	-12,933	-19,532
Operating margin	neg	neg	neg	neg	neg
Results from other financial fixed assets	-	-34	-	-34	-1,690
Financial net	-497	-1,419	-1,672	-1,987	-3,596
Profit before tax	-5,938	-4,526	-14,850	-14,954	-24,817
Tax	-	-4	0	-61	-86
Profit for the period	-5,938	-4,530	-14,850	-15,015	-24,903
Items that may be subsequently reclassified to profit of loss					
Gains/losses arising on translation of the statements of foreign operations	-270	-182	-410	91	-
Comprehensive income of the period	-6,208	-4,711	-15,260	-14,923	-24,903
Profit for the period attributable to Owners of the Parent Company	-5,938	-4,530	-14,850	-15,015	-24,903
Comprehensive income for the period attributable to Owners of the Parent Company	-6,208	-4,711	-15,260	-14,923	-24,903

The Group's statement of financial position in summary

Amount in KSEK	30/Sep 2025	30/Sep 2024	31/Dec 2024
Fixed assets			
Intangible assets	34,895	23,574	28,067
Tangible assets	3,137	4,201	5,012
Financial assets	2,347	4,000	2,310
Total fixed assets	40,379	31,775	35,389
Current assets			
Inventory	5,114	9,510	7,610
Accounts receivable	2,829	6,529	3,398
Other receivable	2,485	5,267	1,657
Prepaid expenses and accrued income	8,449	13,236	8,572
Cash	953	2,122	7,281
Total current assets	19,830	36,664	28,518
TOTAL ASSETS	60,209	68,439	63,907
SHAREHOLDERS' EQUITY	-22,425	2,381	-7,165
PROVISIONS	84	61	89
Long term liabilities			
Long-term interest-bearing liabilities	926	864	2,136
Loan	50,439	-	33,664
Lease liabilities	-	1,258	1,981
Total long term liabilities	51,365	2,122	37,781
Short term liabilities			
Advance payment from customers	4,395	7,191	4,873
Accounts payable	8,026	4,820	7,378
Short term liabilities	1,004	34,414	500
Other liabilities	5,303	3,171	7,774
Lease liabilities	1,981	1,797	1,885
Accrued expenses and prepaid income	10,476	12,482	10,792
Total short term liabilities	31,185	63,875	33,202
TOTAL LIABILITIES AND EQUITY	60,209	68,439	63,907

The Group's statement of changes in equity

Amount in KSEK	30/Sep 2025	30/Sep 2024	31/Dec 2024
Opening balance	-7,165	17,305	17,305
Profit for the period	-15,260	-14,923	-24,903
Currency adjustment	-	-	434
Closing balance	-22,425	2,381	-7,165

The Group's statement of cash flow in summary

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Profit before tax	-5,938	-4,492	-14,850	-14,920	-24,817
Adjustments for non-cash items	808	805	3,137	1,871	5,141
Cash flow from operating activities before changes in working capital	-5,130	-3,687	-11,713	-13,049	-19,676
Cash flow from changes in working capital	1,319	-11,962	-1,666	-7,803	9,929
Cash flow from operating activities	-3,811	-15,649	-13,379	-20,852	-9,747
Cash flow from investing activities	-1,931	-1,260	-8,543	-1,987	-7,590
Cash flow from financing activities	5,097	15,996	15,594	23,672	23,330
Cash flow for the period	-645	-913	-6,328	833	5,993
Cash at the beginning of the period	1,598	2,654	7,281	1,288	1,289
Exchange difference in cash	0	381	0	1	0
Cash at the end of the period	953	2,122	953	2,122	7,281

The Parent Company's income statement in summary

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Net sales	4,883	6,075	14,449	10,786	16,231
Cost of sales	-1,245	-	-4,227	-	-
Gross profit	3,638	6,075	10,222	10,786	16,231
Gross margin	75%	100%	71%	100%	100%
Selling expenses	-	-	-	-	-
Administrative expenses	-2,654	-2,436	-7,395	-8,660	-13,224
Research and development expenses	-62	-	-185	-	-
Other operating income	-	13	-	13	13
Other operating expenses	-	-	-	-63	-63
Operating profit	922	3,652	2,642	2,076	2,957
Operating margin	19%	60%	18%	19%	18%
Income from investments in group companies	-	-50,034	-	-50,034	-50,034
Financial net	-817	-624	-2,327	-2,021	-2,754
Profit before tax	105	-47,006	315	-49,979	-49,831
Tax	-	-	-	-	-
Profit after tax	105	-47,006	315	-49,979	-49,831

The Parent Company's statement of financial position in summary

Amount in KSEK	30/Sep 2025	30/Sep 2024	31/Dec 2024
Fixed assets			
Intangible assets	1,045	514	1,230
Participation in group companies	60,009	60,009	60,009
Total fixed assets	61,054	60,523	61,239
Current assets			
Accounts receivables	-	6,914	210
Receivables from group companies	28,673	14,499	7,060
Tax receivables	182	620	146
Other receivables	396	152	191
Prepaid expenses and accrued income	330	604	765
Cash	7	768	67
Total current assets	29,588	23,557	8,438
TOTAL ASSETS	90,642	84,080	69,677
SHAREHOLDERS' EQUITY	32,170	31,707	31,855
Long term liabilities			
Long-term loans	50,439	-	33,664
Total long term liabilities	50,439	-	33,664
Short term liabilities			
Advance payments from customers	699	750	375
Accounts payable	1,305	1,029	1,183
Tax liabilities	-	-	-
Short-term loan	-	7,000	-
Liabilities to group company	1,195	33,664	278
Other liabilities	980	628	78
Accrued expenses and prepaid income	3,854	1,593	2,244
Total short term liabilities	8,033	52,372	4,158
TOTAL LIABILITIES AND EQUITY	90,642	84,080	69,677

The Parent Company's statement of changes in equity

Amount in KSEK	30/Sep 2025	30/Sep 2024	31/Dec 2024
Opening balance	31,855	81,686	81,686
Profit of the year	315	-49,979	-49,831
Closing balance	32,170	31,707	31,855

Note 1 General information

Ortivus AB (publ), corporate identity number 556259-1205, is a Swedish public limited company with its registered office in Danderyd. The head office is located at Svärdvägen 19, SE-182 33 Danderyd, Sweden. The Group provides digital medical technology and eHealth solutions, specifically developed for out-of-hospital care. Unless otherwise stated, all amounts are reported in thousands of SEK (KSEK). Figures in parentheses refer to the comparative period. This interim report was approved for publication by the Board of Directors on November 28 2025.

Note 2 Accounting principles

This interim report for the Group has been prepared in accordance with IAS 34 Interim Financial Reporting and the Swedish Annual Accounts Act. The interim report for the Parent Company has been prepared in accordance with the Swedish Annual Accounts Act. The same accounting and valuation principles have been applied for the Group and the Parent Company as in the most recently published annual report. Significant estimates and judgements are described in Note 29 of the 2024 Annual Report.

Note 3 Significant risks and uncertainties

Due to the nature of its operations, Ortivus is exposed to various types of risks. The Board's work on risk management is outlined in Note 26 of the 2024 annual report.

Note 4 Revenue distribution

The Group has only one operating segment, which is fully reflected in the Group's financial reports. Revenue is distributed geographically as shown in the table below.

	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Nordics	6,491	11,969	22,491	32,481	43,450
Rest of Europe	10,008	7,314	30,965	25,501	35,419
Rest of the world	350	129	1,194	1,169	1,544
Total	16,849	19,412	54,650	59,151	80,413

Note 5 Significant exchange rates

30 September 2025	EUR	GBP	SGD	USD
Closing rate	11.06	12.66	7.30	9.42
Average rate Q3	11.12	12.84	7.42	9.52
30 September 2024	EUR	GBP	SGD	USD
Closing rate	11.30	13.53	7.88	10.09
Average rate Q3	11.45	13.55	7.90	10.43

Note 6 Alternative performance measures

Ortivus applies the European Securities and Markets Authority's (ESMA) guidelines for so-called Alternative Performance Measures (APMs). The company's management considers these alternative performance measures to be relevant for users of the financial report as a complement to the metrics that reflect the company's operational development. These financial measures are not always comparable with those used by other companies, as not all companies calculate such measures in the same way. Therefore, these financial measures should not be regarded as substitutes for measures defined in accordance with IFRS.

Definitions of key performance indicators

The Group

Gross margin - Gross profit as a percentage of net sales. The company believes that key figures provide a deeper understanding of the Company's profitability.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Gross profit/	4,450	9,107	21,991	23,516	27,935
Net sales	16,849	19,412	54,650	59,151	80,413
Gross margin	26%	47%	40%	40%	35%

Adjusted gross margin - Adjusted gross margin for non-recurring items. Significant events and transactions that are relevant to consider when comparing one period's results with another. Non-recurring items refer to restructuring costs (consultancy fees, costs related to staff reductions, loss-making contracts, and impairments), significant customer losses, as well as disputes and insurance cases. Non-recurring items are excluded to facilitate comparisons of results between periods.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Gross profit	4,450	9,107	21,991	23,516	27,935
EO items	0	0	5,121	0	5,500
Adjusted gross profit/	4,450	9,107	27,112	23,516	33,435
Net sales	16,849	19,412	54,650	59,151	80,413
Adjusted gross margin	26%	47%	50%	40%	42%

Operating margin - Operating margin as a percentage of net sales. The Company believes that key figures provide a deeper understanding of the company's profitability.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Operating results/	-5,441	-3,073	-13,177	-12,933	-19,532
Net sales	16,849	19,412	54,650	59,151	80,413
Operating margin	-32%	-16%	-24%	-22%	-24%

EBITDA - Operating profit before net interest, tax, depreciation of tangible and intangible fixed assets. The Company believes that the key figure provides a deeper understanding of the Company's profitability.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Profit before tax	5,938	4,526	14,850	14,954	24,817
Financial net	497	1,453	1,672	2,021	5,286
Depreciation	1,089	2,887	2,739	3,695	5,686
EBITDA	-4,352	-186	-10,439	-9,238	-13,846

Adjusted EBITDA - Adjusted EBITDA for non-recurring items. Significant events and transactions that are relevant to consider when comparing one period's results with another. Non-recurring items refer to restructuring costs (consultancy fees, costs related to staff reductions, loss-making contracts, and impairments), significant customer losses, as well as disputes and insurance cases. Non-recurring items are excluded to facilitate comparisons of results between periods.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
EBITDA	-4,352	-186	-10,439	-9,238	-13,846
EO costs	0	0	5,121	0	8,915
Adjusted EBITDA	-4,352	-186	-5,318	-9,238	-4,931

Solidity - Equity as a percentage of total assets. Equity ratio shows what proportion of the balance sheet total is made up of equity and has been included so that investors can form a picture of the Company's capital structure.


Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Equity at the end of the period/	-22,425	2,381	-22,425	2,381	-7,165
The balance sheet	60,209	68,439	60,209	68,439	63,907
Solidity	-37%	3%	-37%	3%	-11%

Earnings per share - Profit after tax divided by the average number of shares for the period.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Profit after tax	-5,938	-4,530	-14,850	-15,015	-24,903
Average number of shares for the period (a thousand pcs)	44,307	44,307	44,307	44,307	44,307
Earnings per share	-0.13	-0.10	-0.34	-0.34	-0.56

Equity per share - Equity at the end of the period divided by the number of shares at the end of the period. The Company considers this key figure to provide a deeper understanding of the Company's profitability.

Amount in KSEK	Jul-Sep 2025	Jul-Sep 2024	Jan-Sep 2025	Jan-Sep 2024	Jan-Dec 2024
Equity at the end of the period/	-22,425	2,381	-22,425	2,381	-7,165
Number of shares at the end of the period	44,307	44,307	44,307	44,307	44,307
Equity per share	-0.51	0.05	-0.51	0.05	-0.16



Ortivus

To ensure a smooth and efficient healthcare chain

Our vision

To support healthcare organisations in providing the best care to their patients.

Our mission

To develop and implement innovative software solutions that improve diagnostics, documentation and patient outcomes in the delivery of care.

Our business idea

To provide a digital platform for ambulance and prehospital care that optimises patient flows in real time.

Ortivus platform

MobiMed

MobiMed ePR

MobiMed ePR gathers all essential patient information in an intuitive interface, making it easier to make informed decisions in real time and ensuring high-quality care documentation.

MobiMed Monitor

MobiMed Monitor enables real-time monitoring of vital signs directly in the ambulance, providing a stronger basis for decision-making during emergency interventions.

MobiMed FleetCtrl

MobiMed FleetCtrl offers automated checks, status monitoring, and seamless communication between vehicles and personnel, reducing operational disruptions and improving availability.

MobiMed enRoute

MobiMed enRoute combines advanced navigation with case management, facilitating planning, communication, and follow-up during every mission.

MobiMed Life

MobiMed Life is a portable, standalone defibrillator solution that provides immediate access to life-saving treatment and complements the ambulance's existing equipment.

Ortivus AB

Address

Box 713
Svärdvägen 19
182 33 Danderyd
Sweden

Email

info@ortivus.com

www.ortivus.com

Phone

+ 46 8 446 45 00



Saving. Vital. Seconds.